Sirona Biochem (TSXV:SBM) - Share price, News & Analysis

SBM fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

SBM Stock Overview

Sirona Biochem Corp., a cosmetic ingredient and drug discovery company, develops and sells cosmetic and pharmaceutical active ingredients in Canada and France.

Risk Analysis

Earnings have declined by 1.1% per year over past 5 years

Has less than 1 year of cash runway

Makes less than USD$1m in revenue (CA$59K)

Shareholders have been diluted in the past year

+ 1 more risk

Sirona Biochem Competitors

Covalon Technologies

TSXV:COV

CA$70.3m

Alpha Cognition

TSXV:ACOG

CA$42.7m

Defence Therapeutics

CNSX:DTC

CA$76.3m

Gemina Laboratories

CNSX:GLAB

CA$28.9m

Price History & Performance

Summary of all time highs, changes and price drops for Sirona Biochem
Historical stock prices
Current Share Price	CA$0.18
52 Week High	CA$0.35
52 Week Low	CA$0.14
Beta	-0.70
1 Month Change	-11.91%
3 Month Change	-7.50%
1 Year Change	-11.91%
3 Year Change	-58.89%
5 Year Change	27.59%
Change since IPO	68.18%

Shareholder Returns

	SBM	CA Biotechs	CA Market
7D	0%	-3.5%	2.5%
1Y	-11.9%	13.7%	1.0%

Return vs Industry: SBM underperformed the Canadian Biotechs industry which returned 11.1% over the past year.

Return vs Market: SBM underperformed the Canadian Market which returned 0.7% over the past year.

Price Volatility

Is SBM's price volatile compared to industry and market?
SBM volatility
SBM Average Weekly Movement	13.1%
Biotechs Industry Average Movement	13.0%
Market Average Movement	10.6%
10% most volatile stocks in CA Market	18.9%
10% least volatile stocks in CA Market	4.3%

Stable Share Price: SBM is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: SBM's weekly volatility (13%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2006	n/a	Howard Verrico	https://www.sironabiochem.com

Sirona Biochem Corp., a cosmetic ingredient and drug discovery company, develops and sells cosmetic and pharmaceutical active ingredients in Canada and France. Its programs include cosmetic skin lightener and diabetes drug; and other projects include the development of an anti-aging/cell protection library, novel anti-wrinkle compound, and anti-viral program. The company was formerly known as High Rider Capital Inc. and changed its name to Sirona Biochem Corp. in May 2009.

Sirona Biochem Fundamentals Summary

How do Sirona Biochem's earnings and revenue compare to its market cap?
SBM fundamental statistics
Market Cap	CA$46.57m
Earnings (TTM)	-CA$3.61m
Revenue (TTM)	CA$58.94k

804.3x

P/S Ratio

-12.9x

P/E Ratio

Is SBM overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
SBM income statement (TTM)
Revenue	CA$58.94k
Cost of Revenue	CA$68.77k
Gross Profit	-CA$9.83k
Other Expenses	CA$3.60m
Earnings	-CA$3.61m

Last Reported Earnings

Apr 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-0.014
Gross Margin	-16.68%
Net Profit Margin	-6,119.70%
Debt/Equity Ratio	67.3%

How did SBM perform over the long term?

See historical performance and comparison

We’ve recently updated our valuation analysis.

Valuation

Is SBM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SBM?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for SBM. This is calculated by dividing SBM's market cap by their current preferred multiple.
What is SBM's n/a Ratio?
n/a Ratio	0x
n/a	n/a
Market Cap	CA$46.57m

SBM key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	778.3x
Enterprise Value/EBITDA	-13.2x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does SBM's PB Ratio compare to its peers?

SBM PB Ratio vs Peers

The above table shows the PB ratio for SBM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	PB	Estimated Growth	Market Cap
Peer Average	64.6x
COV Covalon Technologies	2.4x	n/a	CA$70.3m
ACOG Alpha Cognition	4.8x	58.5%	CA$42.7m
DTC Defence Therapeutics	50.4x	n/a	CA$76.3m
GLAB Gemina Laboratories	200.9x	n/a	CA$28.9m
SBM Sirona Biochem	53.5x	n/a	CA$46.6m

Price-To-Book vs Peers: SBM is good value based on its Price-To-Book Ratio (53.5x) compared to the peer average (64.6x).

Price to Earnings Ratio vs Industry

How does SBM's PE Ratio compare vs other companies in the CA Biotechs Industry?

Price-To-Book vs Industry: SBM is expensive based on its Price-To-Book Ratio (53.5x) compared to the Canadian Biotechs industry average (2.7x)

Price to Book Ratio vs Fair Ratio

What is SBM's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SBM PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	53.5x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate SBM's Price-To-Book Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of SBM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate SBM's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate SBM's fair value for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Future Growth

How is Sirona Biochem forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

32.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sirona Biochem has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Discover growth companies

Examine Sirona Biochem's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
Sirona Biochem competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has Sirona Biochem performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-1.1%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: SBM is currently unprofitable.

Growing Profit Margin: SBM is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: SBM is unprofitable, and losses have increased over the past 5 years at a rate of 1.1% per year.

Accelerating Growth: Unable to compare SBM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SBM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).

Return on Equity

High ROE: SBM has a negative Return on Equity (-413.97%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is Sirona Biochem's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: SBM's short term assets (CA$2.0M) exceed its short term liabilities (CA$743.3K).

Long Term Liabilities: SBM's short term assets (CA$2.0M) exceed its long term liabilities (CA$411.7K).

Debt to Equity History and Analysis

Debt Level: SBM has more cash than its total debt.

Reducing Debt: SBM's debt to equity ratio has reduced from 414.5% to 67.3% over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SBM has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: SBM has less than a year of cash runway if free cash flow continues to reduce at historical rates of 2% each year

Discover healthy companies

Dividend

What is Sirona Biochem current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate SBM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SBM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SBM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SBM's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as SBM has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

10.4yrs

Average management tenure

CEO

Howard Verrico (61 yo)

8.17yrs

Tenure

CA$161,280

Compensation

Dr. Howard J. Verrico, M.D., Ph D, is the Founder of Sirona Biochem Corp., has been Chief Executive Officer since June 18, 2014 and serves as its Secretary. Dr. Verrico served as the Chief Executive Office...

CEO Compensation Analysis

Compensation vs Market: Howard's total compensation ($USD125.03K) is below average for companies of similar size in the Canadian market ($USD186.79K).

Compensation vs Earnings: Howard's compensation has been consistent with company performance over the past year.

Leadership Team

Experienced Management: SBM's management team is seasoned and experienced (10.4 years average tenure).

Board Members

Experienced Board: SBM's board of directors are seasoned and experienced ( 12.2 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.3%.

Data	Last Updated (UTC time)
Company Analysis	2022/08/15 00:00
End of Day Share Price	2022/08/15 00:00
Earnings	2022/04/30
Annual Earnings	2021/10/31